
Vaccines Market Size, Share, and Analysis, By Technology (Conjugate, Recombinant, Live Attenuated, Toxoid, Viral Vector, and mRNA), By Type (Monovalent and Multivalent), By Disease (Pneumococcal, Flu, HPV, Herpes Zoster, MMR, Rotavirus, and RSV), By Route
Description
Vaccines Market Size, Share, and Analysis, By Technology (Conjugate, Recombinant, Live Attenuated, Toxoid, Viral Vector, and mRNA), By Type (Monovalent and Multivalent), By Disease (Pneumococcal, Flu, HPV, Herpes Zoster, MMR, Rotavirus, and RSV), By Route of Administration (Parenteral and Oral), By Region (North America, Europe, Asia-Pacific, and Rest of the World), And Regional Forecast 2024-2034
PRODUCT OVERVIEW
Vaccines Market is anticipated to exhibit a Compound Annual Growth Rate (CAGR) of 5.7% during the forecast span from 2024 to 2034. In 2023, the market size was assessed at USD 66.4 billion and is projected to reach USD 122.8 billion by the completion of 2034.
Vaccines are biological preparations designed to boost the immune system and protect against infectious diseases. They consist of weakened or inactivated versions of disease-causing pathogens, such as viruses or bacteria, or components of these agents. When vaccines are administered, the body's immune system identifies the unfamiliar elements and generates antibodies and other active measures to fight against them. This method prepares the immune system to react efficiently in case of future exposure to the real pathogen, thereby averting or reducing the severity of the disease. Therefore, vaccinations are among the most effective public health measures, which annually save millions of lives by averting various diseases such as polio, measles, flu, and most recently, COVID-19.
MARKET HIGHLIGHTS
Vaccine market is projected to reach USD 122.8 billion over the forecast period, due to several factors such as the COVID-19 pandemic, various breakthroughs in technology, and growing awareness of the importance of immunization. Industry players are heavily invested in research and development, which leads to the introduction of new vaccines targeting a wide range of infectious diseases. In addition, the vaccine market has witnessed a rise in demand for COVID-19 vaccines, with companies like Pfizer, Moderna, and AstraZeneca playing important roles in their development and distribution. Besides, the resurgence of infectious diseases like influenza and the growing incidences of chronic diseases have generated the need for preventive measures. Furthermore, collaborations between pharma companies and government agencies have assisted in the development of new vaccine candidates.
Vaccines Market Segments:
Growth Drivers
Innovations in Medical Technology Fuels the Growth of Vaccines Market
Growing Awareness and Government Efforts are Promoting the Need for Vaccines
Restraint
Vaccine Hesitancy and Misinformation in the Vaccines Market
Key Players
Qualitative and quantitative analysis of the market based on segmentation involving both economic as well as non-economic factors
PRODUCT OVERVIEW
Vaccines Market is anticipated to exhibit a Compound Annual Growth Rate (CAGR) of 5.7% during the forecast span from 2024 to 2034. In 2023, the market size was assessed at USD 66.4 billion and is projected to reach USD 122.8 billion by the completion of 2034.
Vaccines are biological preparations designed to boost the immune system and protect against infectious diseases. They consist of weakened or inactivated versions of disease-causing pathogens, such as viruses or bacteria, or components of these agents. When vaccines are administered, the body's immune system identifies the unfamiliar elements and generates antibodies and other active measures to fight against them. This method prepares the immune system to react efficiently in case of future exposure to the real pathogen, thereby averting or reducing the severity of the disease. Therefore, vaccinations are among the most effective public health measures, which annually save millions of lives by averting various diseases such as polio, measles, flu, and most recently, COVID-19.
MARKET HIGHLIGHTS
Vaccine market is projected to reach USD 122.8 billion over the forecast period, due to several factors such as the COVID-19 pandemic, various breakthroughs in technology, and growing awareness of the importance of immunization. Industry players are heavily invested in research and development, which leads to the introduction of new vaccines targeting a wide range of infectious diseases. In addition, the vaccine market has witnessed a rise in demand for COVID-19 vaccines, with companies like Pfizer, Moderna, and AstraZeneca playing important roles in their development and distribution. Besides, the resurgence of infectious diseases like influenza and the growing incidences of chronic diseases have generated the need for preventive measures. Furthermore, collaborations between pharma companies and government agencies have assisted in the development of new vaccine candidates.
Vaccines Market Segments:
- By Technology
- Conjugate
- Recombinant
- Live Attenuated
- Toxoid
- Viral Vector
- mRNA
- By Type
- Monovalent
- Multivalent
- By Disease
- Pneumococcal
- Flu
- HPV
- Herpes Zoster
- MMR
- Rotavirus
- RSV
- By Route of Administration
- Parenteral
- Oral
Growth Drivers
Innovations in Medical Technology Fuels the Growth of Vaccines Market
Growing Awareness and Government Efforts are Promoting the Need for Vaccines
Restraint
Vaccine Hesitancy and Misinformation in the Vaccines Market
Key Players
- Pfizer
- GlaxoSmithKline (GSK)
- Merck & Co.
- Sanofi Pasteur
- Serum Institute of India
- AstraZeneca
- Novavax
- Moderna
- Johnson & Johnson
- CSL Limited
- Bharat Biotech
- Sinovac Biotech
- CanSino Biologics
- Dynavax Technologies
- Valneva
- Other Prominent Players (Company Overview, Business Strategy, Key Product Offerings, Financial Performance, Key Performance Indicators, Risk Analysis, Recent Development, Regional Presence, SWOT Analysis)
- North America Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAG.R – United States and Canada
- Latin America Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – Mexico, Argentina, Brazil and Rest of Latin America
- Europe Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – United Kingdom, France, Germany, Italy, Spain, Belgium, Hungary, Luxembourg, Netherlands, Poland, NORDIC, Russia, Turkey and Rest of Europe
- Asia Pacific Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – India, China, South Korea, Japan, Malaysia, Indonesia, New Zealand, Australia and Rest of APAC
- Middle East and Africa Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – North Africa, Israel, GCC, South Africa and Rest of MENA
Qualitative and quantitative analysis of the market based on segmentation involving both economic as well as non-economic factors
- Provision of market value (USD Billion) data for each segment and sub-segment
- Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
- Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
- Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
- Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
- The current as well as the future market outlook of the industry with respect to recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
- Includes in-depth analysis of the market of various perspectives through Porter’s five forces analysis
- Provides insight into the market through Value Chain
- Market dynamics scenario, along with growth opportunities of the market in the years to come
- 3-month post-sales analyst support.
Table of Contents
560 Pages
- 1. Executive Summary
- 1.1 Regional Market Share
- 1.2. Business Trends
- 1.3 Vaccines Market: COVID-19 Outbreak
- 1.4 Regional Trends
- 1.5. Segmentation Snapshot
- 2. Research Methodology
- 2.1. Research Objective
- 2.2 Research Approach
- 2.3 Data Sourcing and Methodology
- 2.4. Primary Research
- 2.5. Secondary Research
- 2.5.1. Paid Sources
- 2.5.2 Public Sources
- 2.6 Market Size Estimation and Data Triangulation
- 3. Market Characteristics
- 3.1. Market Definition
- 3.2 Vaccines Market: COVID-19 Impact
- 3.3 Key Segmentations
- 3.4. Key Developments
- 3.5. Allied Industry Data
- 4. Vaccines Market – Industry Insights
- 4.1 Industry Segmentation
- 4.2. COVID-19 overview of world economy
- 4.3. Industry Ecosystem Channel Analysis
- 4.4. Innovation & Sustainability
- 5. Macroeconomic Indicators
- 6. Recent Developments
- 7 Market Dynamics
- 7.1. Introduction
- 7.2 Growth Drivers
- 7.3 Market Opportunities
- 7.4. Market Restraints
- 7.5 Market Trends
- 8. Risk Analysis
- 9. Market Analysis
- 9.1. Porter's Five Forces
- 9.2 PEST Analysis
- 9.2.1. Political
- 9.2.2 Economic
- 9.2.3 Social
- 9.2.4 Technological
- 10. Vaccines Market
- 10.1 Overview
- 10.2. Historical Analysis (2019-2022)
- 10.2.1. Market Size, Y-o-Y Growth (%) and Market Forecast
- 11 Vaccines Market Size & Forecast 202 A-203 F
- 11.1 Overview
- 11.2. Key Findings
- 11.3. Market Segmentation
- 11.3.1. By Technology
- 11.3.1.1. Conjugate
- 11.3.1.1.1. By Value (USD Million) 2024-203 F
- 11.3.1.1.2 Market Share (%) 2024-203 F
- 11.3.1.1.3 Y-o-Y Growth (%) 2024-203 F
- 11.3.1.2 Recombinant
- 11.3.1.2.1 By Value (USD Million) 2024-203 F
- 11.3.1.2.2. Market Share (%) 2024-203 F
- 11.3.1.2.3. Y-o-Y Growth (%) 2024-203 F
- 11.3.1.3 Live Attenuated
- 11.3.1.3.1 By Value (USD Million) 2024-203 F
- 11.3.1.3.2. Market Share (%) 2024-203 F
- 11.3.1.3.3. Y-o-Y Growth (%) 2024-203 F
- 11.3.1.4 Toxoid
- 11.3.1.4.1 By Value (USD Million) 2024-203 F
- 11.3.1.4.2. Market Share (%) 2024-203 F
- 11.3.1.4.3. Y-o-Y Growth (%) 2024-203 F
- 11.3.1.5 Viral Vector
- 11.3.1.5.1 By Value (USD Million) 2024-203 F
- 11.3.1.5.2. Market Share (%) 2024-203 F
- 11.3.1.5.3. Y-o-Y Growth (%) 2024-203 F
- 11.3.1.6 mRNA
- 11.3.1.6.1 By Value (USD Million) 2024-203 F
- 11.3.1.6.2. Market Share (%) 2024-203 F
- 11.3.1.6.3. Y-o-Y Growth (%) 2024-203 F
- 11.3.2. By Type
- 11.3.2.1 Monovalent
- 11.3.2.1.1 By Value (USD Million) 2024-203 F
- 11.3.2.1.2. Market Share (%) 2024-203 F
- 11.3.2.1.3. Y-o-Y Growth (%) 2024-203 F
- 11.3.2.2. Multivalent
- 11.3.2.2.1. By Value (USD Million) 2024-203 F
- 11.3.2.2.2 Market Share (%) 2024-203 F
- 11.3.2.2.3 Y-o-Y Growth (%) 2024-203 F
- 11.3.3. By Disease
- 11.3.3.1 Pneumococcal
- 11.3.3.1.1 By Value (USD Million) 2024-203 F
- 11.3.3.1.2. Market Share (%) 2024-203 F
- 11.3.3.1.3. Y-o-Y Growth (%) 2024-203 F
- 11.3.3.2. Flu
- 11.3.3.2.1. By Value (USD Million) 2024-203 F
- 11.3.3.2.2 Market Share (%) 2024-203 F
- 11.3.3.2.3 Y-o-Y Growth (%) 2024-203 F
- 11.3.3.3. HPV
- 11.3.3.3.1. By Value (USD Million) 2024-203 F
- 11.3.3.3.2 Market Share (%) 2024-203 F
- 11.3.3.3.3 Y-o-Y Growth (%) 2024-203 F
- 11.3.3.4. Herpes Zoster
- 11.3.3.4.1. By Value (USD Million) 2024-203 F
- 11.3.3.4.2. Market Share (%) 2024-203 F
- 11.3.3.4.3. Y-o-Y Growth (%) 2024-203 F
- 11.3.3.5. MMR
- 11.3.3.5.1. By Value (USD Million) 2024-203 F
- 11.3.3.5.2 Market Share (%) 2024-203 F
- 11.3.3.5.3 Y-o-Y Growth (%) 2024-203 F
- 11.3.3.6. Rotavirus
- 11.3.3.6.1. By Value (USD Million) 2024-203 F
- 11.3.3.6.2 Market Share (%) 2024-203 F
- 11.3.3.6.3 Y-o-Y Growth (%) 2024-203 F
- 11.3.3.7. RSV
- 11.3.3.7.1. By Value (USD Million) 2024-203 F
- 11.3.3.7.2 Market Share (%) 2024-203 F
- 11.3.3.7.3 Y-o-Y Growth (%) 2024-203 F
- 11.3.4. By Route of Administration
- 11.3.4.1 Parenteral
- 11.3.4.1.1 By Value (USD Million) 2024-203 F
- 11.3.4.1.2. Market Share (%) 2024-203 F
- 11.3.4.1.3. Y-o-Y Growth (%) 2024-203 F
- 11.3.4.2. Oral
- 11.3.4.2.1. By Value (USD Million) 2024-203 F
- 11.3.4.2.2 Market Share (%) 2024-203 F
- 11.3.4.2.3. Y-o-Y Growth (%) 2024-203 F
- 12. North America Vaccines Market Size & Forecast 202 A-203 F
- 12.1. Overview
- 12.2. Key Findings
- 12.3. Market Segmentation
- 12.3.1. By Technology
- 12.3.2 By Type
- 12.3.3 By Disease
- 12.3.4 By Route of Administration
- 12.4. Country
- 12.4.1 United States
- 12.4.2. Canada
- 13. Europe Vaccines Market Size & Forecast 202 A-203 F
- 13.1. Overview
- 13.2. Key Findings
- 13.3. Market Segmentation
- 13.3.1. By Technology
- 13.3.2 By Type
- 13.3.3 By Disease
- 13.3.4 By Route of Administration
- 13.4. Country
- 13.4.1 Germany
- 13.4.2 United Kingdom
- 13.4.3 France
- 13.4.4. Italy
- 13.4.5 Spain
- 13.4.6 Russia
- 13.4.7 Rest of Europe (BENELUX, NORDIC, Hungary, Turkey & Poland)
- 14. Asia-Pacific Vaccines Market Size & Forecast 202 A-203 F
- 14.1 Overview
- 14.2. Key Findings
- 14.3. Market Segmentation
- 14.3.1. By Technology
- 14.3.2 By Type
- 14.3.3 By Disease
- 14.3.4. By Route of Administration
- 14.4. Country
- 14.4.1. India
- 14.4.2 China
- 14.4.3. South Korea
- 14.4.4. Japan
- 14.4.5. Rest of APAC
- 15. Middle East and Africa Vaccines Market Size & Forecast 202 A-203 F
- 15.1 Overview
- 15.2. Key Findings
- 15.3. Market Segmentation
- 15.3.1. By Technology
- 15.3.2 By Type
- 15.3.3 By Disease
- 15.3.4 By Route of Administration
- 15.4. Country
- 15.4.1 Israel
- 15.4.2. GCC
- 15.4.3. North Africa
- 15.4.4 South Africa
- 15.4.5. Rest of Middle East and Africa
- 16. Latin America Vaccines Market Size & Forecast 202 A-203 F
- 16.1. Overview
- 16.2. Key Findings
- 16.3. Market Segmentation
- 16.3.1. By Technology
- 16.3.2 By Type
- 16.3.3 By Disease
- 16.3.4 By Route of Administration
- 16.4. Country
- 16.4.1. Mexico
- 16.4.2. Brazil
- 16.4.3. Rest of Latin America
- 17. Competitive Landscape
- 17.1. Company market share, 2023
- 17.2 Key player overview
- 17.3. Key stakeholders
- 18. Company Profiles
- 18.1 Pfizer
- 18.1.1 Company Overview
- 18.1.2 Financial Overview
- 18.1.3 Key Product; Analysis
- 18.1.4 Company Assessment
- 18.1.4.1 Product Portfolio
- 18.1.4.2. Key Clients
- 18.1.4.3. Market Share
- 18.1.4.4. Recent News & Development (Last 3 Yrs.)
- 18.1.4.5. Executive Team
- 18.2 GlaxoSmithKline (GSK)
- 18.3 Merck & Co.
- 18.4 Sanofi Pasteur
- 18.5 Serum Institute of India
- 18.6 AstraZeneca
- 18.7 Novavax
- 18.8 Moderna
- 18.9 Johnson & Johnson
- 18.10 CSL Limited
- 18.11. Bharat Biotech
- 18.12 Sinovac Biotech
- 18.13 CanSino Biologics
- 18.14 Dynavax Technologies
- 18.15 Valneva
- 18.16 Other Prominent Players
- 19. Appendix
- 20 Consultant Recommendation
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.